MedTrace Logo

The Efficacy of B6 and Metoclopramide Combination in Comparison With the Other Antiemetics

NCT06390787 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-04-30

No results posted yet for this study

Summary

This study investigates the effectiveness of combining vitamin B6 (pyridoxine) and metoclopramide compared to standard antiemetic treatments for managing nausea and vomiting. Through a prospective, randomized controlled trial involving adult patients with diverse causes of nausea and vomiting, we aim to evaluate the frequency, severity, and tolerability of the B6 and metoclopramide combination. By elucidating its comparative efficacy against established antiemetics, this research seeks to provide evidence-based guidance for clinicians in selecting optimal treatment regimens tailored to individual patient needs, ultimately enhancing the management of nausea and vomiting across various medical conditions.

Conditions

Interventions

DRUG

Metoclopramide and Vitamin B6

We gave a combination of vitamin B6 (pyridoxine) and metoclopramide as a treatment for managing nausea and vomiting.

DRUG

Vitamin B6

We gave only vitamin B6 (pyridoxine) as a treatment for managing nausea and vomiting.

DRUG

Ondansetron

We gave only Zofran as a treatment for managing nausea and vomiting.

DRUG

Metoclopramide

We gave only Metoclopramide as a treatment for managing nausea and vomiting.

Sponsors & Collaborators

  • University of Baghdad

    lead OTHER

Principal Investigators

  • Hashim Talib T Hashim, MBChB · University of Warith Al-Anbiyaa, College of Medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-30
Primary Completion
2024-04-20
Completion
2024-04-21

Countries

  • Iraq

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06390787 on ClinicalTrials.gov